Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MYELOPROLIFERATIVE DISORDERS

Finding the right KIT inhibitor for advanced systemic mastocytosis

Nature Medicine volume 27, pages 2081–2082 (2021)Cite this article

Subjects

Two early-phase clinical trials show impressive response rates and symptom improvement with the selective KIT inhibitor avapritinib, which will provide a much-needed new treatment option for patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: SM symptoms, mediators and organ impact of indolent and advanced disease.

References

  1. Valent, P., Akin, C. & Metcalfe, D. D. Blood 129, 1420–1427 (2017).

    Article  CAS  Google Scholar 

  2. Metcalfe, D. D. J. Invest. Dermatol. 96, 2S–4S (1991).

    Article  Google Scholar 

  3. Castells, M. & Austen, K. F. Int. Arch. Allergy Immunol. 127, 147–152 (2002).

    Article  CAS  Google Scholar 

  4. Theoharides, T. C., Valent, P. & Akin, C. N. Engl. J. Med. 373, 163–172 (2015).

    Article  CAS  Google Scholar 

  5. Escribano, L., Akin, C., Castells, M., Orfao, A. & Metcalfe, D. D. Ann. Hematol. 81, 677–690 (2002).

    Article  CAS  Google Scholar 

  6. Escribano, L. et al. J. Allergy Clin. Immunol. 124, 514–521 (2009).

    Article  Google Scholar 

  7. Lim, K. H. et al. Blood 113, 5727–5736 (2009).

    Article  CAS  Google Scholar 

  8. Nagata, H. et al. Proc. Natl Acad. Sci. USA 92, 10560–10564 (1995).

    Article  CAS  Google Scholar 

  9. DeAngelo, D. J. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01538-9 (2021).

  10. Gotlib, J. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01539-8 (2021).

  11. Gotlib, J. et al. N. Engl. J. Med. 374, 2530–2541 (2016).

    Article  CAS  Google Scholar 

  12. Castells, M. & Butterfield, J. J. Allergy Clin. Immunol. Pract. 7, 1097–1106 (2019).

    Article  Google Scholar 

  13. Akin et al. J. Allergy Clin. Immunol. 145, AB336 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA, USA

    Mariana Castells

  2. Department of Medicine, Harvard Medical School, Boston, MA, USA

    Mariana Castells

  3. Division of Allergy and Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    Cem Akin

Authors
  1. Mariana Castells
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cem Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariana Castells.

Ethics declarations

Competing interests

M.C. and C.A. have consultancy agreement with and receive research funding from Blueprint Medicines.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castells, M., Akin, C. Finding the right KIT inhibitor for advanced systemic mastocytosis. Nat Med 27, 2081–2082 (2021). https://doi.org/10.1038/s41591-021-01588-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01588-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer